The global dry age-related macular degeneration market is entering a transformative phase, underpinned by demographic shifts, advancing medical technologies, and robust research investments. Valued at USD 5.27 billion in 2024, the market is projected to reach USD 10.58 billion by 2032, growing at a CAGR of 9.1% from 2025 to 2032. This expansion reflects the rising prevalence of AMD worldwide and the accelerating demand for effective diagnostic and treatment solutions.
Quick Market Insights
Market Valuation (2024): USD 5.27 billion
Forecasted Value (2032): USD 10.58 billion
CAGR (2025–2032): 9.1%
Key Growth Drivers: Aging population, technological innovation, and new therapeutic developments
Major Restraints: High treatment burden and lack of curative options
Stay Informed on Key Market Changes: Get a Sample Report: https://www.snsinsider.com/sample-request/2627
A Growing Health Concern: The Aging Population and AMD Incidence
Dry AMD is one of the leading causes of vision impairment and blindness in older adults, with cases expected to surge alongside global aging trends. In the United States, the population aged 65 years and older is anticipated to increase from 58 million in 2022 to 82 million by 2050, significantly expanding the patient pool at risk for macular degeneration.
Beyond aging, the disease burden is intensified by modifiable lifestyle factors, such as smoking, excessive alcohol consumption, poor diet, and physical inactivity, which have been linked to increased AMD incidence. The growing awareness of preventive eye care and early screening has driven greater attention to dry AMD management, encouraging market adoption of novel diagnostic tools and therapies.
Technological Advancements Driving Early Detection
Technological evolution in diagnostic imaging and teleophthalmology has revolutionized the way AMD is detected and managed. The introduction of high-resolution optical coherence tomography (OCT) and fundus autofluorescence imaging allows ophthalmologists to identify early-stage macular changes and monitor disease progression with precision.
Simultaneously, the integration of digital monitoring platforms and AI-assisted image analysis enables remote consultations and real-time follow-up, improving access to care for elderly patients and those in remote areas. These innovations are contributing to better outcomes and more efficient healthcare delivery in AMD management.
Innovation in Therapeutics: Expanding Treatment Horizons
Pharmaceutical and biotechnology companies are investing heavily in developing novel therapeutics for dry AMD, focusing on mechanisms such as anti-inflammatory, neuroprotective, and complement pathway modulation. The traditional lack of effective pharmacological interventions for dry AMD is now being addressed through emerging drug candidates, gene therapy, and stem cell-based treatments.
Recent advancements include complement inhibitors that target the underlying pathophysiology of AMD, aiming to slow or halt retinal degeneration. Research on cell-based regenerative approaches is also gaining momentum, promising potential for vision restoration in advanced cases.
Collaborations between biotech firms, academic research institutions, and clinical centers have created a strong pipeline of experimental drugs currently in Phase II and III trials, reflecting the market’s dynamic innovation landscape.
Market Drivers and Restraints
The key drivers of the dry AMD market include a rapidly aging global population, rising disease prevalence, and continuous technological and therapeutic advancements. Increased healthcare expenditure and improved reimbursement frameworks in major economies further enhance patient access to diagnostic and treatment options.
However, the market also faces certain restraints. The lack of curative treatments, coupled with the high treatment burden associated with frequent intravitreal injections, continues to challenge patient compliance and healthcare costs. Additionally, off-label drug use remains prevalent in some regions, affecting market standardization and clinical outcomes. Despite these challenges, the ongoing focus on innovation and precision medicine offers significant avenues for overcoming such barriers.
Opportunities and Challenges Ahead
The dry AMD market presents vast opportunities in next-generation therapeutics, particularly in gene editing, neuroprotection, and combination therapies. As clinical research deepens the understanding of disease mechanisms, pharmaceutical firms are poised to introduce more targeted and personalized treatment options.
Moreover, the integration of AI and telemedicine into ophthalmic care will continue to enhance early detection, patient monitoring, and treatment adherence. Expanding healthcare infrastructure in emerging markets, particularly across Asia-Pacific and Latin America, presents new opportunities for market penetration.
Conversely, challenges such as regulatory complexities, high R&D costs, and variability in clinical outcomes across patient populations may constrain the pace of innovation. Addressing these issues through global research partnerships, supportive policy frameworks, and strategic investments will be essential for sustained growth.
Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report: https://www.snsinsider.com/reports/dry-age-related-macular-degeneration-market-2627
Market Segmentation Overview
The dry age-related macular degeneration market is segmented across multiple parameters, offering insights into diverse areas of growth:
By Stages, the market includes Early AMD, Intermediate AMD, and Late AMD, with late-stage conditions accounting for a significant revenue share due to advanced treatment interventions.
By End User, the market encompasses Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes, and Others, with hospitals leading in patient diagnosis and treatment adoption.
By Age Group, segments include Above 40 Years, Above 60 Years, and Above 75 Years, reflecting the progressive nature of AMD across age demographics.
By Diagnosis & Treatment, the market is divided into Treatment and Diagnosis, where the treatment segment is witnessing rapid advancements due to innovative therapeutic developments.
By Route of Administration, both Oral and Injectable options are gaining traction, with injectables currently dominating due to the delivery of anti-VEGF and other ophthalmic drugs.
Regional Insights
North America dominates the dry AMD market, driven by strong healthcare infrastructure, high disease awareness, and robust R&D activities. The U.S. remains the leading contributor, supported by the presence of major pharmaceutical companies and extensive clinical research initiatives.
Europe follows closely, with countries such as Germany, the UK, and France investing in advanced ophthalmic diagnostics and innovative treatment technologies. Favorable reimbursement systems and an aging population continue to drive demand across the region.
In the Asia-Pacific, rapid population aging, increasing healthcare spending, and the expansion of ophthalmology networks in China, Japan, and India are catalyzing market growth. This region presents untapped potential for global manufacturers due to its large patient base and emerging regulatory support for innovative therapies.
Meanwhile, Latin America and the Middle East & Africa are experiencing gradual progress, supported by growing healthcare investments and enhanced awareness campaigns targeting retinal diseases.
Competitive Landscape
Key players operating in the global dry AMD market include Bayer AG, Pfizer Inc., Amgen Inc., Biogen, Novartis AG, F. Hoffmann-La Roche Ltd., Samsung Bioepis, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceuticals Inc., Allergan plc, Alimera Sciences Inc., Phio Pharmaceuticals Corp., Iveric Bio, Belite Bio Inc., Ocumension Therapeutics Co. Ltd., Eyestem Research Pvt Ltd, and Kubota Vision Inc.
These companies are actively engaged in strategic partnerships, product innovation, and clinical research collaborations to strengthen their portfolios and expand their global footprint. The competitive environment is characterized by pipeline diversification, technological integration, and accelerated regulatory approvals.
Conclusion
The dry age-related macular degeneration market is evolving rapidly, driven by a confluence of demographic, technological, and scientific factors. As global research accelerates toward disease-modifying therapies, the coming decade is expected to redefine AMD management with a focus on precision medicine, teleophthalmology, and regenerative treatments.
With increasing investments from leading pharmaceutical giants and the expansion of diagnostic infrastructure worldwide, the dry AMD market stands at the cusp of a breakthrough era—one that promises enhanced patient outcomes, improved accessibility, and sustained growth through 2032.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
